Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 337 followers
Latest posts
Last updated about 9 hours ago
US taps small San Diego biotech for experimental Ebola treatment as epidemic worsens
about 9 hours ago
As an outbreak of Ebola in central Africa continues to worsen, the...
GHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm
about 12 hours ago
London-based Global Healthcare Opportunities and Singapore-based CBC Group announced plans to merge...
Qiagen links with chip giant Nvidia to propel AI use in drug discovery
about 14 hours ago
Qiagen, a Netherlands-based diagnostics maker, is linking with tech giant Nvidia in...
Lilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues
about 17 hours ago
San Carlos-based Engage is developing non-viral DNA delivery systems that aim to...
With $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate
about 18 hours ago
In the sprawling metropolis of Houston, a new biotech has emerged to...
Incyte pays Genesis $80M to expand AI-fueled drug discovery pact
about 18 hours ago
Incyte is paying Genesis $80 million upfront to expand use of its...
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows
about 18 hours ago
BMS is the latest large pharma company to make a major bet...
Labcorp joins lab results personalization push with ‘MyLabcorp’ AI app
about 19 hours ago
The big new thing in medtech for 2026 is AI-powered apps and...
Immunovant pays out $39M to call time on FcRn inhibitor after eye disease phase 3 fails
about 20 hours ago
Immunovant has confirmed that its first-generation FcRn inhibitor has been scrapped, with...
Endologix acquires thrombectomy system from Surmodics
about 20 hours ago
Endologix, a medtech that focuses on treatments for vascular diseases, expanded its...
Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug’s phase 3 push
about 23 hours ago
With the ink barely dry on an antibody-drug conjugate-style deal with Regeneron...
Pfizer furthers pneumococcal efforts, remains ‘comfortable’ taking on emerging threats: vaccine chief
about 23 hours ago
After decades of developing vaccines to shield babies and adults from Streptococcus...